Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
01 1 » 1 1 (Expand Search), 0 1 (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
01 1 » 1 1 (Expand Search), 0 1 (Expand Search)
-
221
-
222
-
223
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
-
224
Annual treatment frequencies in all eyes.
Published 2025“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
225
-
226
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
227
Annual number of outpatient visits in all eyes.
Published 2025“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
228
-
229
EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi<sub>0.8</sub>Co<sub>0.1</sub>Mn<sub>0.1<...
Published 2023“…Besides, the electrochemical properties of the batteries during cold conditions can be obviously improved by adding EB. In addition, after 50 cycles of −40 °C, the basic electrolyte has a discharge capacity of 81.94 mAh g<sup>–1</sup>; on the contrary, the cells using the 16 EB-modified coreagent maintains a discharge capacity of 112.3 mAh g<sup>–1</sup> under the same conditions. …”
-
230
EB (Ethyl Butyrate) as a Cosolvent of Electrolyte Tuning an Ultrathin CEI Membrane for Improving the Ultralow-Temperature Behaviors of LiNi<sub>0.8</sub>Co<sub>0.1</sub>Mn<sub>0.1<...
Published 2023“…Besides, the electrochemical properties of the batteries during cold conditions can be obviously improved by adding EB. In addition, after 50 cycles of −40 °C, the basic electrolyte has a discharge capacity of 81.94 mAh g<sup>–1</sup>; on the contrary, the cells using the 16 EB-modified coreagent maintains a discharge capacity of 112.3 mAh g<sup>–1</sup> under the same conditions. …”
-
231
-
232
-
233
-
234
-
235
-
236
-
237
-
238
Inhibiting Gamma-secretase activity without interfering in Notch signaling: Decreasing the inflammatory response in patients with cutaneous leishmaniasis
Published 2020“…Pearson’s test was used for correlation statistical analysis and p value is represented according to the size of the circles.; *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.</p><p><b>Figure 3 - Non-selective gamma-secretase inhibitor (DAPT) decreases inflammatory-associated proteins production from CL patients in response to <i>Leishmania</i>antigens.…”
-
239
-
240